Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended‐release naltrexone in a residential setting
Authors:
Open Access
- 9 February 2022
- journal article
- research article
- Published by Wiley in The American Journal on Addictions
- Vol. 31 (2) , 142-147
Abstract
Background and Objectives: Treatment for individuals receiving medication for opioid use disorder (MOUD) should follow an informed patient‐centered approach. To better support patient autonomy in the decision‐making process, clinicians should be aware of patient preferences and be prepared to educate and assist patients in transitioning from one MOUD to another, when clinically indicated. This posthoc analysis describes the characteristics of clinical trial participants (NCT02696434) with a history of opioid use disorder (OUD) seeking to transition from buprenorphine (BUP) to extended‐release naltrexone (XR‐NTX).Methods: The posthoc analysis included adults with OUD currently receiving BUP (≤8 mg/day) and seeking transition to XR‐NTX (N = 101) in a residential setting. Baseline participant characteristics and OUD treatment history were reviewed. All patients completed a screening questionnaire that asked about their reasons for seeking transition to XR‐NTX and for choosing BUP.Results: The most common reasons for initiating a transition to XR‐NTX were “Seeking to be opioid‐free” (63.4%) and “Tired of daily pill taking” (25.7%). Positive predictors of transition included a more extensive BUP treatment history and a history of prescription opioid abuse. Most participants stated they were not aware of XR‐NTX as a treatment option when initiating BUP (78.2%).Discussions and Conclusions: Patients' reasons for seeking XR‐NTX transition, more extensive BUP treatment history, and a history of prescription opioid abuse, may positively predict outcomes.Scientific Significance: These findings may assist clinicians in optimizing outcomes of the BUP to XR‐NTX transition and supporting patients to make better informed MOUD decisions.Keywords
This publication has 11 references indexed in Scilit:
- Correlates of Patient-Centered Care Practices at U.S. Substance Use Disorder ClinicsPsychiatric Services, 2020
- Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use DisorderJournal of Addiction Medicine, 2019
- Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical CorrelatesThe American Journal on Addictions, 2019
- A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practicesInternational Journal of Drug Policy, 2018
- Acceptability of Extended-Release Naltrexone by Heroin-Dependent Patients and Addiction Treatment Providers in the NetherlandsSubstance Use & Misuse, 2016
- Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid DetoxificationJournal of Substance Abuse Treatment, 2016
- Patient Perspectives Associated with Intended Duration of Buprenorphine Maintenance TherapyJournal of Substance Abuse Treatment, 2015
- Baseline characteristics of patients predicting suitability for rapid naltrexone inductionThe American Journal on Addictions, 2015
- Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid DependenceArchives of General Psychiatry, 2011
- “Should I stay or should I go?” Coming off methadone and buprenorphine treatmentInternational Journal of Drug Policy, 2011